Psoriasis – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of psoriasis (PsO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PsO for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature pharmaceutical markets (United States, European countries, and Japan) and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s PsO forecast will answer the following questions:

• Of all people diagnosed with PsO, how many in each of the developed countries are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PsO over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 10 PsO patient populations, including the following:

• Diagnosed 12-month prevalent cases of PsO.
• Diagnosed 12-month prevalent cases of mild PsO.
• Diagnosed 12-month prevalent cases of moderate PsO.
• Diagnosed 12-month prevalent cases of severe PsO.
• Diagnosed 12-month prevalent cases of drug-treated PsO.
• Diagnosed 12-month prevalent cases of plaque PsO.

Note: Coverage may vary by country.